Patients received either BIIB122 or a placebo for 48 to 144 weeks.

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the ...

Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing ...

Shares of Biogen (BIIB) and Denali Therapeutics (DNLI) fell in the premarket on Friday after the companies announced a decision to discontinue the development of BIIB122, an experimental therapy for ...

Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle ...

Parkinson drug development halted as Biogen and Denali stop BIIB122 after phase 2b trial failed to slow disease progression.

The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, the company said.

Biogen and Denali Therapeutics halted development of experimental Parkinson's therapy BIIB122 after the Phase 2b LUMA study failed to meet its endpoints. Legal investigations have been launched into ...

The partners will stop developing BIIB122 in an all-comer population, but Denali will keep evaluating it in those with LRRK2 pathogenic variants.

Denali Therapeutics Inc. DNLI initiated dosing in a global mid-stage study, BEACON, on BIIB122 (DNL151). BIIB122, an investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor, is being ...

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the ...